Table 1. Characteristics of studies included in primary analysis.
| Study | Trial Phase | Tumor Type | Concurrent Treatment | No in intervention/control* | Bevacizumab dose, mg/kg per week | Jadad score |
| Bennouna, 2013 | III | Colorectal cancer | bolus fluorouracil or capecitabine plus oxaliplatin or irinotecan | 401/409 | 2.5 | 3 |
| Giantonio, 2007 | III | Colorectal cancer | Oxaliplatin, fluorouracil, leucovorin | 287/285 | 5 | 2 |
| de Gramont, 2012 | III | Colon cancer | Fluorouracil, leucovorin, oxaliplatin | 1145/1126 | 2.5 | 3 |
| Guan, 2011 | III | Colorectal cancer | Irinotecan, leucovorin bolus, 5-fluorouracil | 141/70 | 2.5 | 3 |
| Hurwitz, 2004 | III | Colorectal cancer | Irinotecan, leucovorin, bolus fluorouracil | 393/397 | 2.5 | 3 |
| Kabbinavar, 2003 | II | Colorectal cancer | Fluorouracil, leucovorin | 67/35 | 2.5 or 5 | 2 |
| Kabbinavar, 2005 | II | Colorectal cancer | Bolus fluorouracil, leucovorin | 100/104 | 2.5 | 3 |
| Saltz, 2008 | III | Colorectal cancer | Oxaliplatin, fluorouracil, and folinic or capecitabine and oxaliplatin | 694/675 | 2.5 | 4 |
| Tebbutt, 2010 | III | Colorectal cancer | Capecitabine | 157/156 | 2.5 | 3 |
| Bear, 2012 | III | Breast cancer | capecitabine or gemcitabine plus docetaxel | 595/596 | 5 | 2 |
| Brufsky, 2011 | III | Breast cancer | Docetaxel or gemcitabine or capecitabine or vinorelbine | 458/221 | 5 | 4 |
| Cameron, 2013 | III | Breast cancer | Anthracycline or taxane | 1288/1271 | 5 | 3 |
| Gianni, 2013 | III | Breast cancer | Docetaxel, trastuzumab | 215/206 | 5 | 2 |
| Martin, 2011 | II | Breast cancer | Paclitaxel | 96/89 | 5 | 3 |
| Miles, 2010 | II | Breast cancer | Docetaxel | 499/231 | 2.5 or 5 | 3 |
| Miller, 2005 | III | Breast cancer | Capecitabine | 229/215 | 5 | 2 |
| Miller, 2007 | III | Breast cancer | Paclitaxel | 365/346 | 5 | 3 |
| Robert, 2011 | III | Breast cancer | Docetaxel, capecitabine, anthracycline | 817/403 | 5 | 3 |
| Herbst, 2007 | II | NSCLC | Docetaxel, pemetrexed | 39/42 | 5 | 3 |
| Herbst, 2011 | III | NSCLC | Erlotinib | 313/313 | 5 | 4 |
| Johnson, 2004 | II | NSCLC | Paclitaxel, carboplatin | 66/32 | 2.5 or 5 | 3 |
| Niho, 2012 | II | NSCLC | Carboplatin, paclitaxel | 119/58 | 5 | 2 |
| Reck, 2009 | III | NSCLC | Cisplatin, gemcitabine | 659/327 | 2.5 or 5 | 4 |
| Sandler, 2006 | III | NSCLC | Carboplatin, paclitaxel | 427/440 | 5 | 3 |
| Aghajanian, 2012 | III | Ovarian, peritoneal, fallopian tube cancer | Gemcitabine, carboplatin | 242/242 | 5 | 4 |
| Burger, 2011 | III | Ovarian cancer | Carboplatin, paclitaxel | 608/601 | 5 | 3 |
| Perren, 2011 | III | Ovarian cancer | Carboplatin, paclitaxel | 745/753 | 2.5 | 3 |
| Escudier, 2007 | III | Renal cell carcinoma | interferon alfa | 337/304 | 5 | 4 |
| Rini, 2010 | III | Renal cell carcinoma | Interferon alfa | 362/347 | 5 | 2 |
| Van Cutsem, 2009 | III | Pancreatic cancer | Gemcitabine, erlotinib | 296/287 | 2.5 | 4 |
| Kindler, 2010 | III | Pancreatic cancer | Gemcitabine | 277/263 | 2.5 | 4 |
| Kelly, 2012 | III | Prostate cancer | Docetaxel, prednisone | 504/505 | 5 | 3 |
| Ohtsu, 2011 | III | Gastric cancer | fluoropyrimidine, cisplatin | 386/381 | 2.5 | 4 |
| Spigel, 2011 | II | SCLC | Cisplatin or carboplatin plus etoposide | 51/47 | 5 | 4 |
*Number of patients for safety analysis; NSCLC, non– small cell lung cancer; SCLC, small cell lung cancer.